Catheter Precision (VTAK) Exec Chairman Receives 500,000-Option Grant

Rhea-AI Filing Summary

David A. Jenkins, Executive Chairman of the Board of Catheter Precision, Inc. (VTAK), was granted 500,000 stock option awards on 08/12/2025. The options have an exercise price of $0.18 per share, an exercisable date listed as 08/12/2025 and an expiration date of 08/12/2035. The filing shows 500,000 underlying shares of common stock beneficially owned following the transaction, held directly. The options vest at 20% per year beginning on the first anniversary of the grant date, according to the explanation in the filing.

Positive

• 500,000 stock options granted to Executive Chairman David A. Jenkins, as disclosed in the Form 4
• Options have clear terms: $0.18 exercise price, 08/12/2025 exercisable date, and 08/12/2035 expiration
• Vesting schedule is specified: 20% per year beginning on the first anniversary of the grant date
• Post-transaction beneficial ownership is explicitly reported as 500,000 shares held directly

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Executive chairman received a 10-year option grant for 500,000 shares with multi-year vesting.

The Form 4 discloses a standard equity-based compensation grant to the Executive Chairman, aligning long-term interests through a ten-year term and graded vesting of 20% per year after the first anniversary. The exercise price of $0.18 is explicitly stated, and ownership is reported as direct for 500,000 shares following the grant. This is a routine disclosure of insider compensation; the filing does not include other contextual details such as grant valuation, reason for grant, or prior holdings beyond the post-transaction balance.

Securities Analyst

TL;DR: Insider received a sizeable option grant; filing reports clear grant mechanics but no financial impact metrics.

The Form 4 provides concrete grant terms: 500,000 options, $0.18 strike, exercisable 08/12/2025, expiring 08/12/2035, with 20% annual vesting commencing one year after grant. The report shows the options convert to 500,000 shares of common stock and are reported as directly beneficially owned. The document contains no revenue, market cap, or dilution calculations, so material financial impact cannot be quantified from this filing alone.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JENKINS DAVID A

(Last) (First) (Middle)

1670 HIGHWAY 160 WEST

SUITE 205

(Street)

FORT MILL SC 29708

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Catheter Precision, Inc. [ VTAK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Exec. Chairman of the Board

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options (Right to Buy)	$0.18	08/12/2025		A		500,000		(1)	08/12/2035	Common Stock	500,000	$0	500,000	D

Explanation of Responses:

1. Options vests 20% per year beginning on first anniversary of grant date.

	/s/ David Jenkins	08/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for VTAK?

The Form 4 was filed by David A. Jenkins, Executive Chairman of Catheter Precision, Inc.

What security and amount were reported on the Form 4 for VTAK?

The filing reports an award of 500,000 stock options exercisable into common stock.

What are the exercise price and key dates for the options reported for VTAK?

The options have an exercise price of $0.18, an exercisable date of 08/12/2025, and an expiration date of 08/12/2035.

What is the vesting schedule for the options disclosed in the VTAK Form 4?

The options vest at 20% per year beginning on the first anniversary of the grant date, per the filing explanation.

How many shares are beneficially owned following the reported transaction for VTAK?

The Form 4 reports 500,000 shares of common stock beneficially owned following the transaction, held directly.